grant
Dissecting the Acid Ceramidase Pathway in Hepatic Fibrogenesis
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 15 Aug 2023Deadline 31 May 2028
NIHUS FederalResearch GrantFY2025AblationAcid CeramidaseAffectAmericanAssayAtomic Force MicroscopyBioassayBiochemicalBiological AssayBiological MarkersCell BodyCell Communication and SignalingCell SignalingCell-Extracellular MatrixCellsCeramide Signaling PathwayCeramide TrihexosidaseCeramidesCessation of lifeCharacteristicsChronicClinicalClinical TreatmentCollagenDataDeathDepositDepositionDevelopmentDiagnosisDiagnostic testsDiseaseDisease ProgressionDisorderECMEnzyme GeneEnzymesExtracellular MatrixExtracellular Matrix DegradationFDA approvedFibrosisForce MicroscopyGenesGoalsHepatic FailureHepatic FibrogenesisHepatic Stellate CellHumanHydrolysisIn VitroInterstitial CollagenaseIntracellular Communication and SignalingIto CellKO miceKnock-out MiceKnockout MiceKnowledgeLKB1LKB1/STK11 GeneLifeLiverLiver FailureLiver FibrosisMMP-1MMP-1Fibroblast CollagenaseMMP1MMPsMatrix Metalloproteinase-1Matrix MetalloproteinasesMediatingMediatorMissionModelingModern ManModificationMolecularNAFLDNational Institutes of HealthNull MouseOutcomePathway interactionsPatientsPlayPublic HealthPublishingRegulationResearchResolutionRoleSTK11STK11 geneSamplingScanning Force MicroscopySeveritiesSignal PathwaySignal TransductionSignal Transduction SystemsSignalingStressTechniquesTestingTherapeuticUnited States National Institutes of HealthWorkantifibrotic agentantifibrotic medicationantifibrotic therapyantifibrotic treatmentattenuationbio-markersbiologic markerbiological signal transductionbiomarkerchronic hepatic diseasechronic hepatic disorderchronic liver diseasechronic liver disorderclinical diagnosticsclinical interventionclinical relevanceclinical therapyclinically relevantcohortconditional knock-outconditional knockoutdevelopmentaldisease heterogeneityeffective therapyeffective treatmentend stage liver diseaseend stage liver failurefibrogenesisfibrotic livergain of functiongalactosylgalactosylglucosylceramidasegene signaturesgenetic signaturehepatic body systemhepatic fibrosishepatic organ systemimprovedin vivoliver fibrogenesisliver kinase B1loss of functionmedical diagnosticnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-alcohol fatty liver diseasenon-alcoholic fatty liver diseasenon-alcoholic liver diseasenonalcoholic fatty liver diseasenovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathwaypatient biomarkerspatient populationpatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespersonalization of treatmentpersonalized medicinepersonalized therapypersonalized treatmentpreventpreventingresolutionsresponseside effectsocial rolespecific biomarkerstrial regimentrial treatment
Description preview
ABSTRACT
Fibrosis is the final common pathway in chronic liver disease that leads to liver failure, and is characterized by
an imbalance of extracellular matrix (ECM) deposition and remodeling. There are currently no FDA-approved
therapies to target this endpoint of chronic liver disease. Moreover, there is a paucity of biomarkers that reflect…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click